PL
AERI

Parkwood LLC’s Aerie Pharmaceuticals AERI Stock Holding History

Parkwood LLC’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,657
Closed -$483K – 538
2017
Q1 		$483K Sell
10,657
-2,500
-19% -$111K 0.07% 198
2016
Q4 		$498K Buy
+13,157
New +$498K 0.08% 181

Other funds holding AERI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Parkwood LLC's AERI Position: Q2 2017 in Review

Parkwood LLC sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 10,657 shares — an estimated $483K sold.

Parkwood LLC first reported a position in AERI in Q4 2016 and held it in 2 quarters. The position peaked at $498K in Q4 2016. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

  • Parkwood LLC reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Parkwood LLC sold 10,657 Aerie Pharmaceuticals shares in Q2 2017, an estimated $483K.
  • Parkwood LLC first reported a position in Aerie Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Parkwood LLC's Aerie Pharmaceuticals position peaked at $498K in Q4 2016.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Parkwood LLC's 13F filing for Q2 2017, filed 25 Jul 2017.